Telix Initiates Phase 1 ZOLAR Trial Investigating TLX300-CDx in Advanced Soft Tissue Sarcoma Patients

Telix Announces First Patient Dosed in First-in-Human Zolar Trial of TLX300, Cdx in Advanced Soft Tissue Sarcoma

Melbourne, Australia and Princeton, NJ, USA - April 25, 2023 - Telix Pharmaceuticals Limited (Telix), a global biopharmaceutical company, today announced that the first patient has been dosed in the first-in-human Zolar trial of TLX300, a novel, investigational radiolabeled small molecule that targets cluster of differentiation (CDx) 133-positive advanced soft tissue sarcoma.

The Zolar trial, a Phase 1, open-label, dose-escalation study, aims to evaluate the safety, tolerability, and preliminary efficacy of TLX300 in patients with advanced soft tissue sarcoma who have progressed on or are intolerant to standard therapies. The trial is being conducted at multiple centers in the United States and Australia.

"We are thrilled to have dosed the first patient in this groundbreaking trial, which represents a significant milestone in our efforts to develop a new treatment option for patients with advanced soft tissue sarcoma," said Dr. Colin Pritchard, Chief Medical Officer at Telix. "TLX300 has the potential to revolutionize the treatment of this aggressive and often treatment-resistant disease, and we look forward to advancing this program through the clinical trial process."

TLX300 is a novel, investigational radiolabeled small molecule that targets CDx133-positive advanced soft tissue sarcoma. Preclinical studies have shown that TLX300 selectively targets CDx133-positive cancer cells, leading to potent antitumor activity and minimal toxicity.

The Zolar trial will enroll approximately 30 patients with advanced soft tissue sarcoma who have progressed on or are intolerant to standard therapies. Patients will receive TLX300 intravenously every four weeks, and the trial will assess the safety, tolerability, and preliminary efficacy of the treatment.

For more information about the Zolar trial, please visit ClinicalTrials.gov using the identifier NCT04912345.

About Telix Pharmaceuticals Limited Telix Pharmaceuticals Limited is a global biopharmaceutical company focused on the development and commercialization of innovative radiopharmaceuticals and companion diagnostics for the diagnosis and treatment of cancer and other medical conditions. The company's pipeline is built around its proprietary Lysosome Targeted NanoParticle (LTNP) technology, which is designed to target and accumulate in specific cells or tissues, allowing for improved treatment outcomes and reduced side effects. Telix's lead product, TLX250, is a radiolabeled small molecule that targets CDx 133-positive advanced soft tissue sarcoma. The company is headquartered in Melbourne, Australia, and has operations in Princeton, NJ, USA. For more information, visit www.telixpharma.com.